Orthocell appoints distributor for flagship nerve repair product in Hong Kong

• Orthocell appoints exclusive in-country distributor for flagship nerve-repair product Remplir in Hong Kong
• MontsMed is a highly credentialled medical device distribution company in Hong Kong
• First surgical cases and sales in Hong Kong expected in the near term

Special Report: Orthocell has strengthened its commercial reach in Asia with the appointment of MontsMed as exclusive in-country distributor for its flagship nerve-repair device Remplir in Hong Kong.

First surgical cases and sales are expected soon, following regulatory approval in May from Hong Kong’s Department of Health’s Medical Device Division.

Remplir is a collagen wrap used to assist surgeons in repairing and regenerating damaged nerves, improving outcomes after injury.

Hong Kong’s position as a recognised medical hub makes it a strategically valuable component of Orthocell’s (ASX: OCC) global footprint, as the company targets the estimated US$3.5 billion global nerve-repair market.

Supported by a strong balance sheet of more than $50 million in cash, Orthocell says it is well funded to broaden its commercial footprint and grow revenues across existing and new markets.

Pathway to market in key growth hub

Approval in Hong Kong also opens a pathway for Remplir to the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) under the Regulatory Innovation and Development of Pharmaceutical and Medical Device work plan.

The framework allows designated healthcare institutions within the GBA – spanning nine cities and about 100 million people – to import Hong Kong-registered medical devices to meet urgent clinical needs.

Building momentum in Singapore and Thailand

The Hong Kong appointment complements Orthocell’s progress in Singapore, where Device Technologies Asia acts as exclusive distributor and sales momentum continues to build, supported by strong relationships with leading plastic reconstructive and orthopaedic surgeons.

In Thailand, where Remplir already has regulatory approval, the company is assessing potential local distributors ahead of expected sales in 2026.

Across its Remplir and Striate+ product lines, Orthocell has developed significant expertise in managing partnerships across multiple global jurisdictions – a foundation that supports its continued scale-up across Asia.

Watch: US Remplir rollout 

New commercial director appointed

The regional rollout is being led by newly appointed commercial director Hamish Thrum, based in Australia.

Thrum recently returned from 13 years in Singapore, where he held senior roles at Johnson & Johnson, Smith & Nephew, and orthopaedic start-up Zeda.

Orthocell said his deep knowledge of the ANZ and APAC markets and established relationships with surgeons and distributors would be invaluable as the company continues to expand Remplir’s Asian footprint.

‘Key step’ in Asian commercialisation strategy

CEO and managing director Paul Anderson said Orthocell was approaching the commercialisation of Remplir in Asia on a country-by-country basis in a very deliberate and considered manner.

“The appointment of MontsMed as our exclusive distributor in Hong Kong is a key step in our Asian commercialisation strategy,” he said.

“We initially identified Singapore, Hong Kong and Thailand as our primary targets in Asia.

“With regulatory approvals achieved and distributors now in place in two of three markets, we are focused on strategies to achieve market penetration in those countries.

Anderson said it made sense to continue to appoint in-country distributors in each of the Asian markets as they hold direct relationships with surgeons and hospitals.

“We have made the decision to appoint a commercial director to drive this program with Hamish bringing strong Asian medical sales experience to focus on driving this process and we welcome him to the Orthocell senior executive team.”

This article was developed in collaboration with Orthocell, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.